Benzothiazol-2-ylcarboxylic acids with diverse spacers: A novel class of potent, orally active aldose reductase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 13, 1997, Pages 1677-1682

  Aotsuka, Tomoji ^a   Abe, Naoki ^a   Fukushima, Kanako ^a   Ashizawa, Naoki ^a   Yoshida, Motoyuki ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; BENZOIC ACID DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; GLYCERALDEHYDE; PHENYLACETIC ACID DERIVATIVE; SORBITOL; TOLRESTAT; ZENARESTAT; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; CYCLIZATION; DIABETES MELLITUS; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; LENS; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; SWINE;

EID: 0030838802     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00287-4     Document Type: Article

References (17)

1. (a) Kador, P. F. Med. Res. Rev. 1988, 8, 325;
2. (b) Lipinski, C. A.; Huston, N. J. Annu. Rep. Med. Chem. 1984, 19, 169;
3. (c) Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. J. Med. Chem. 1985, 28, 841;
4. (d) Kador, P. F.; Robinson W. G.; Kinoshita, J. H. Annu. Rev. Pharmacol. Toxicol. 1985, 25, 691.
5. Itoh, Y.; Ao, S.; Notsu, Y.; Hashimoto, M. Drugs of the future 1992, 17, 31.
6. Aotsuka, T.; Hosono, H.; Kurihara, T.; Nakamura, Y.; Matsui, T. Chem. Pharm. Bull. 1994, 42, 1264.
7. Mylari, B. L.; Larson, E. R.; Bayer, T. A.; Zemblowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. J. Med. Chem. 1991, 34, 108.
8. Gameise, D. L.; Paris, G. Y.; Komlossy, J.; Chambers, C. H.; MacCrae, R. C. J. Med. Chem. 1969, 12, 30.
9. Brembilla, A.; Roizard, D.; Lochon, P. Synth. Commun. 1990, 20, 3379.
10. Zieglar, Jr. C. B.; Heck, R. F. J. Org. Chem. 1978, 43, 2941.
11. Bolm, C.; Weickhardt, K.; Zehnder, M.; Ranff, T. Chem. Ber. 1991, 124, 1173.
12. Hayman, S.; Kinoshita, J. H. J. Biol. Chem. 1965, 240, 877.
13. Four, eight and twenty four hours after STZ injection, compounds were administered, see ref. 3.
14. Sastanj, K.; Bellini, F.; Abraham, N.; Tresurywala, A.; Hamber, L.J. Med. Chem. 1984, 27, 255.
15. From 1 week after STZ injection, compounds were administered once daily for 5 days, see: Ashizawa, N.; Yoshida, M.; Sugiyama, Y.; Akaike, N.; Ohbayashi, S.; Aotsuka, T.; Abe, N.; Fukushima, K.; Matsuura, A. Jpn. J. Pharmacol. 1997, 73, 133.
16. 50(AR) was >10,000. Zopolrestat and SG-210 are also AR selective inhibitors. These compounds including GP-1447 possess benzothiazole rings as lipophilic aromatic groups, which may contribute to the enzyme selectivity, see ref. 12 and: Matsui, T.; Nakamura, Y.; Ishikawa, H.; Matsuura, A.; Kobayashi, F. Jpn. J. Pharmacol 1994, 64, 115.
17. Ishii, A.; Kotani, T.; Nagaki, Y.; Shibayama, Y.; Toyomaki, Y.; Okukado, N.; Inaga, K.; Okamoto, K. J. Med. Chem. 1996, 39, 1924.